The anti-B-cell maturation antigen BiTE molecule AMG 420 was assessed in patients with relapsed/refractory multiple myeloma.In this first-in-human study, up to 10 cycles of AMG 420 were given (4-week infusions/6-week […]
Recent Content
- Mapping the Landscape of Quality of Life in Smoldering Multiple Myeloma Clinical Trials: A Systematic Review
- Mo-Rez shows strong early responses in ovarian, endometrial cancers
- FDA grants fast track status to oral therapy for hard-to-treat myeloma
- Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial
- Concordance and prognostic value of bone-marrow MRD and PET-CT in multiple myeloma: a systematic review and meta-analysis
- Advocacy group marks AML Awareness Day with interactive webpage launch
- Daraxonrasib may offer new hope in previously treated pancreatic cancer
- (no title)
- Plixorafenib given FDA breakthrough status for high-grade gliomas
- (no title)